Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluating a Distance Learning Asthma Education Program for Pediatricians (The DALI Study)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00815724
First received: December 29, 2008
Last updated: March 7, 2013
Last verified: March 2013
  Purpose

The National Heart, Lung, and Blood Institute (NHLBI) has established guidelines for treating people with asthma. This study will evaluate the effectiveness of a distance learning program that aims to educate doctors on these guidelines, specifically the use of inhaled corticosteroids to treat asthma in pediatric patients.


Condition Intervention
Asthma
Behavioral: Distributed Asthma Learning Initiative (DALI) distance learning program

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Official Title: Distributed Asthma Learning Initiative

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Change in physician asthma knowledge, attitudes, and treatment behavior [ Time Frame: Measured at Months 1 and 6 ] [ Designated as safety issue: No ]
  • Learner satisfaction [ Time Frame: Measured at Months 1 and 6 ] [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: February 2007
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Participants will take part in a distance learning group.
Behavioral: Distributed Asthma Learning Initiative (DALI) distance learning program
Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
No Intervention: 2
Participants in the control group will not receive any study materials or take part in any study activities.

Detailed Description:

Asthma is a long-term lung disease that affects more than 22 million people in the United States. Symptoms include wheezing, chest tightness, shortness of breath, and coughing. Inhaled corticosteroids are a common medication used to treat asthma. NHLBI has established guidelines for doctors to reference when treating people with asthma. Study researchers previously evaluated a distance learning program aimed to educate doctors on the NHLBI guidelines and to improve pediatrician adherence to the guideline recommendations for the use of daily inhaled corticosteroids for persistent asthma in pediatric patients. This pilot study will evaluate a new version of the distance learning program. By using a distance learning program rather than a traditional face-to-face educational program, participants will be able to complete the program on their own schedule, and this flexibility may result in increased interest in the program. The purpose of this study is to evaluate the effectiveness of the new distance learning program on changing pediatricians' behavior, attitudes, and knowledge regarding the NHLBI guidelines for the use of inhaled corticosteroids to treat pediatric patients with asthma.

This study will enroll pediatricians. Participants will be randomly assigned to either the distance learning group or a control group. At baseline, all participants will complete questionnaires. Participants in the control group will not take part in any of the educational activities. Participants in the distance learning group will take part in a 1-hour Webinar, or teleconference, that will provide an orientation to the program and discuss the importance of the NHLBI guidelines. At any time between the first Webinar and a 6-week follow-up Webinar, participants will log into the study Web site and complete a training module that aims to educate participants on common barriers to prescribing daily inhaled corticosteroids. As an alternative to the Web site, participants may choose to view the training module on a CD-ROM. Six weeks after the first Webinar, participants will take part in a follow-up Webinar. At this time, study researchers will answer participants' questions and provide a program review. The Web site and study materials will remain available to participants in the distance learning group for 6 months after the follow-up Webinar; a list serve will also be made available to participants. At 1 and 6 months after the follow-up Webinar, all participants will complete questionnaires.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Board-eligible pediatricians involved in direct primary care for children
  • Has access to a Windows or Macintosh computer with either a CD-ROM drive or Internet access
  • Has access to a telephone for teleconference calls
  • Willing to take part in the DALI educational seminar if assigned to the intervention group
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00815724

Locations
United States, California
University of California, San Francisco
San Francisco, California, United States, 94118
Sponsors and Collaborators
University of California, San Francisco
Investigators
Principal Investigator: Michael D. Cabana, MD, MPH University of California, San Francisco
Principal Investigator: Tao Le, MD University of Louisville
  More Information

No publications provided

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00815724     History of Changes
Other Study ID Numbers: 621, R01HL070771, R01 HL70771
Study First Received: December 29, 2008
Last Updated: March 7, 2013
Health Authority: United States: Federal Government

Keywords provided by University of California, San Francisco:
Daily Inhaled Corticosteroids
Distributed Learning
E-learning

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 20, 2014